***How to use this template?*** *The template contains sections that can be used when preparing the manuscript. The document's formatting, including font, size, spacing, and other formatting parameters, should be maintained unchanged in accordance with this template. Delete this paragraph and begin filling out all sections.*

**ARTICLE TITLE**

N.MN. SURNAME 1, N.MN. SURNAME 2, N.MN. SURNAME 3

1 Affiliation 1, city, country

2 Affiliation 2, city, country

3 Affiliation 3, city, country

**Abstract**

**For original research articles, systematic reviews, or meta-analyses, the abstract should provide a substantive summary of the work conducted. Authors are strongly encouraged to use the following subheadings. The abstract length should not exceed 300 words.**

**Introduction.** Indicate the broad context in which the research question is considered.

**Aim.** Highlight the aim of the study.

**Materials and Methods.** Briefly describe the main methods or types of therapy applied, including the characteristics of the study population.

**Results.** Summarize the main findings of the article.

**Conclusion.** Reflect the key conclusions or interpretations. The abstract should objectively present the content of the article, not contain results that are not presented and confirmed in the main text, and should not exaggerate the significance of the findings.

**Key words:** 5–6 keywords according to MeSH (<https://www.ncbi.nlm.nih.gov/mesh/>), separated by commas.

**Introduction.** This section should briefly place the study within a broad scientific context and emphasize its significance. It is necessary to define the purpose of the work and its importance. The current state of the research area should be carefully analyzed, with references to key publications. If necessary, controversial and contradictory hypotheses should be noted. In conclusion, briefly state the main objective of the study and highlight the main findings. Whenever possible, present the material in a way that is understandable to scientists working outside your specialized field. References should be cited in the order of appearance and formatted as numbers in square brackets — for example, [1] or [2,3], or [4–6]. Detailed instructions for formatting references are provided at the end of the document.

**Materials and methods.**

In this section, materials and methods should be described in sufficient detail to allow other researchers to reproduce the experiment and rely on the obtained results in the future. Submission of the article for publication implies the author’s willingness to provide readers with all materials, raw data, software code, and protocols used. If there are restrictions on access to any components of the study, this must be reported at the manuscript submission stage. New methodologies and protocols are recommended to be described in detail, whereas well-known approaches can be briefly described with a mandatory reference to the source. If the article contains large-scale data placed in open databases, the exact storage location and access registration numbers must be indicated. Studies involving interventions with animals or humans, as well as other research requiring ethical committee approval, must include information about the organization that issued the authorization and the corresponding approval code. In this regard, the first subsection of this section should be titled «Ethical issues ».

The titles of the subsections should be written in italics. For example:

Ethical issues

The research protocol was reviewed and approved by the Ethics Committee of \_\_\_\_\_\_\_\_\_\_, Republic of Kazakhstan (Protocol No. ? dated dd.mm.yy). All participants provided written informed consent prior to inclusion in the study. During data collection and analysis, anonymity and confidentiality were strictly observed.

Thus, in this “Materials and methods” section, there may be subsections with headings such as “Study design”, “Data collection”, etc. In addition, the last subsection in the “Materials and methods” section should be titled “Statistical Analysis”.

**Results.** This section may be divided into subsections. It should contain a concise and accurate description of the results and their interpretation.  
All figures and tables must be mentioned in the main text as Figure 1, Table 1, etc. Tables and figures should be placed in the main text near their first mention.



**Figure 1.** This is a figure. Diagrams are formatted in the same way. The figure should be centered in the file, and its title should be listed below the drawing.

**Table 1.**This is a table.

|  |  |  |
| --- | --- | --- |
| **Heading 1** | **Heading 2** | **Heading 3** |
| variables | data | data |
| variables | data | data |

1 Tables may have footnotes.

**Discussion.** The authors must provide a discussion of the obtained results, comparing them with data from previously conducted studies and the initial working hypotheses. The interpretation should be carried out in the broadest scientific context, with an emphasis on the theoretical and practical significance of the identified patterns. In addition, it is advisable to outline promising directions for further research. In case factors limiting the conducted study are identified, they should be presented in the final paragraph of this section, highlighted as a separate subsection titled “ Study limitations”.

**Conclusion.** This section is mandatory and should contain the main findings of the study.

**Conflict of interest.**

In this section, authors should disclose the presence or absence of potential or actual conflicts of interest. These include financial relationships, organizational affiliations, consultancies, patents, sponsorships, and any other factors that could influence the interpretation of the results. If there is no conflict of interest, it is recommended to state: "The authors declare no conflict of interest."

**Authors' contribution.**

Concept, XX and YY; methodology, XX; software, XX; validation, XX, YY and ZZ; formal analysis, XX; investigation, XX; resources, XX; data management, XX; writing- preparation of the original manuscript, XX; writing - review and editing, XX; visualization, XX; supervision, XX; project administration, XX; funding acquisition, YY. All authors have read and agreed to the published version of the manuscript." The authors declare that this material has not been previously published and is not under consideration by other publishers. Authorship should be limited to persons who have made a significant contribution to the work.

**Funding.**

Here you should list the sources of funding for your research: grants, programs, projects, sponsorships. You should include the grant number, organization name, and country.

**Acknowledgments.**

Acknowledgements are given here to individuals or organizations that contributed to the research but are not co-authors.

**LIST OF REFERENCES**

The bibliography should be numbered in the order in which it appears in the text (including references in tables and figure captions) and provided as a separate list at the end of the manuscript. We recommend using specialized bibliography management software, such asEndNote to avoid typos and duplicate sources. References are enclosed in square brackets and placed before punctuation. For example: [2], [4–6], [3.5]. For ≤6 authors, all are listed; for >6, the first six and et al. Journal titles are abbreviated according to NLM Catalog. A DOI is required, if available. Sources in Russian or Kazakh are transliterated.

1. Smith J, Brown K, Ahmed R, Li Y, Tanaka H, Ivanov P. Advances in cardiovascular imaging. J Clin Invest. 2022;130(5):1123–34. <https://doi.org/10.1172/JCI123456>
2. Johnson M, Lee A, Chen W, Rodríguez L, Patel R, Müller T, et al. Global strategies for diabetes care. Lancet. 2021;398(10295):1234–45. <https://doi.org/10.1016/S0140-6736(21)00234-1>
3. White P, Black R. Imaging biomarkers. In: Green D, Taylor M, editors. Modern radiology. 2nd ed. New York: Springer; 2020. p. 154–96.
4. Patel R, Müller T. Clinical endocrinology. 3rd ed. London: Elsevier; 2018. p. 200–315.
5. Chen W, Tanaka H. Molecular oncology. Nat Rev Cancer. 2023; in press.
6. World Health Organization (Geneva, Switzerland); National Cancer Institute (Washington, DC, USA). Personal communication, 2021.
7. Li Y, Ahmed R, Ivanov P. Novel tracers for PET/CT. In: Proceedings of the International Congress on Nuclear Medicine; 2022 Sep 12–15; Tokyo, Japan. Tokyo: MedPubl; 2022. p. 50–6.
8. Brown K, White P. Reproductive health and biomarkers. Oxford: Oxford University Press; 2021. p. 50–220.
9. World Health Organization. Coronavirus disease (COVID-19) dashboard [Internet]. Geneva: WHO; 2021 [cited 2025 Oct 2]. Available from: <https://www.who.int>
10. Example of transliteration: Иванов И.В., Петрова А.Н. Современные подходы к терапии миомы матки. Акушерство и гинекология. 2020;10(4):55–62. https://doi.org/10.1234/abcde

Ivanov IV, Petrova AN. Sovremennye podkhody k terapii miomy matki. Akush Ginekol (Mosk). 2020;10(4):55–62. https://doi.org/10.1234/abcde

1. Сейдахметова А.К., Нургалиев Б. Репродукциялық денсаулық биомаркерлері: эпидемиологиялық зерттеу. Ғылым және Білім. 2022;15(2):120–34. https://doi.org/10.5678/xyz123  
   Seidakhmetova AK, Nurgaliyev B. Reproduktsiyalyk densaulyk biomarkerleri: epidemiologiyalyk zertteu. Gylym zhane Bilim. 2022;15(2):120–34. https://doi.org/10.5678/xyz123

**Information about authors** (full names of the authors are indicated in order, the corresponding author’s name is marked with the symbol @ before the information)

Ivanov Sergey Ivanovich, cardiologist, Doctor of Medical Sciences, Head of the Cardiology Department, NJSC "National Scientific Cardiac Surgery Center", Astana, Kazakhstan, ivanovaa@cardio.kz, <https://orcid.org/0000-0001-2345-6789>.

@Kanatov Aidos Ikramovich, bioinformatician, PhD, Private Institution "National Laboratory Astana", Nazarbayev University, Astana, Kazakhstan, seriklyza.bio@gmail.com, https://orcid.org/0000-0002-9876-5432.

**Авторлар туралы мәліметтер**

Иванов Сергей Иванович, кардиолог, м.ғ.д., кардиология бөлімінің меңгерушісі, «Ұлттық ғылыми кардиохирургия орталығы» КЕАҚ, Астана, Қазақстан, ivanovaa@cardio.kz, <https://orcid.org/0000-0001-2345-6789>.

@Канатов Айдос Икрамович, биоинформатик, PhD, «National Laboratory Astana» ЖШҚ, Назарбаев Университеті, Астана, Қазақстан, seriklyza.bio@gmail.com, https://orcid.org/0000-0002-9876-5432.

**Сведения об авторах**

Иванов Сергей Иванович, кардиолог, д.м.н., заведующий отделением кардиологии, НАО "Национальный научный центр кардиохирургии", Астана, Казахстан, [ivanovaa@cardio.kz](mailto:ivanovaa@cardio.kz), <https://orcid.org/0000-0001-2345-6789>.

@Канатов Айдос Икрамович, биоинформатик, PhD, ЧУ «National Laboratory Astana», Назарбаев Университет, Астана, Казахстан, seriklyza.bio@gmail.com, https://orcid.org/0000-0002-9876-5432.

**ARTICLE TITLE** (**in Kazakh)**

N.MN. SURNAME 1, N.MN. SURNAME 2, N.MN. SURNAME 3 (**in Kazakh)**

1 Аффилиация 1, қала, ел

2 Аффилиация 2, қала, ел

3 Аффилиация 3, қала, ел

**Түйіндеме**

**Кіріспе.** Қойылған мәселе қарастырылатын кең контекстті көрсетіңіз.

**Мақсаты.** Зерттеудің мақсатын айқындаңыз.

**Материалдар мен әдістер.** Қолданылған негізгі әдістерді немесе терапия түрлерін қысқаша сипаттаңыз, соның ішінде зерттелген популяцияның сипаттамасын беріңіз.

**Нәтижелер.** Мақаланың негізгі тұжырымдарын жинақтаңыз.

**Қорытынды.** Негізгі қорытындыларды немесе интерпретацияларды көрсетіңіз. Аңдатпа мақала мазмұнын объективті көрсетуі тиіс, негізгі мәтінде ұсынылмаған немесе расталмаған нәтижелерді қамтымауы керек және негізгі қорытындылардың маңызын асыра бағаламауы тиіс.

**Түйінді сөздер:** MeSH (<https://www.ncbi.nlm.nih.gov/mesh/>) бойынша 5–6 түйінді сөзді үтірмен бөліп көрсету қажет.

**ARTICLE TITLE** (**in Russian)**

N.MN. SURNAME 1, N.MN. SURNAME 2, N.MN. SURNAME 3 (**in Russian)**

1 Аффилиация 1, город, страна

2 Аффилиация 2, город, страна

3 Аффилиация 3, город, страна

**Аннотация**

**Введение.** Укажите, в каком широком контексте рассматривается поставленный вопрос.

**Цель.** Подчеркните цель исследования.

**Материалы и методы.** Кратко опишите основные применённые методы или виды терапии, включая характеристику исследуемой популяции.

**Результаты.** Суммируйте основные выводы статьи.

**Заключение.** Отразите ключевые выводы или интерпретации. Аннотация должна объективно представлять содержание статьи, не содержать результатов, которые не представлены и не подтверждены в основном тексте, а также не должна преувеличивать значение основных выводов.

**Ключевые слова:** необходимо привести 5-6 ключевых слов по MeSH (https://www.ncbi.nlm.nih.gov/mesh/), разделенных запятыми.